Year: 2007 Source: Journal of Clinical Psychiatry, v.68, no.7, (July 2007), p.1139-1141 SIEC No: 20090658

In this commentary, the author considers some of the issues faced by the Food & Drug Administration regarding their revision of the black box warning of an increased risk of suicidality with the use of antidepressants. Possible consequences of this decision are discussed. (11 refs.)